SAN FRANCISCO – RDMD, a health care technology company focused on accelerating research for patients with rare diseases, has raised $3 million in seed financing, led by Lux Capital. RDMD has developed a technology platform that generates deep data insights to accelerate rare disease research and drug development, as well as a patient application that enables patients and families to get access to and benefit from their own medical data. “This financing enables us to expand our efforts and tailor our approach for the needs of any rare condition, providing real value for both patients and drug developers,” said Onno Faber, founder, chairman and head of product of RDMD, in a statement. The funding will be used to further develop the company’s platform, expand the leadership team to support demand and growth, generate high quality data, expand into new rare conditions and work with partners to advance their research and development programs. RDMD’s technology platform transforms unstructured data from medical records into disease-specific data models that can be readily analyzed. The company has also partnered with researchers at the National Cancer Institute and the Children’s Tumor Foundation.
You are here: / / RDMD raises $3M for rare disease data platform